[Alpha Biz= Reporter Kim Jisun] Daesang announced that it has acquired a 20% stake in Chengfu, a Chinese L-lysine production company.
According to the Financial Supervisory Service's electronic disclosure system on the 20th, Daesang invested 8.8425 billion KRW to purchase the 20% stake in Chengfu.
Daesang explained, "The purpose of acquiring the stake is to use it as a base for supplying functional feed amino acids through a minority equity investment."
Through this acquisition, Daesang plans to establish a manufacturing base in China and expand its amino acid business.
The stake acquisition had been postponed three times since 2022 before being completed on this day.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
